Kruppel-like factor 5 mRNA (KLF5 mRNA)

Kruppel-like factor 5 (KLF5) mRNA encodes a pro-proliferative zinc-finger transcription factor that is frequently overexpressed in various epithelial cancers, including breast, prostate, and colorectal cancers (NCBI Gene ID: 688; UniProt: Q13887). It functions as a key regulator of the G1/S phase transition by activating the transcription of cell cycle genes like CCND1 (Cyclin D1) and CDC25A, while suppressing pro-apoptotic signals (PMID: 30655533). In the context of oncology, KLF5 mRNA is considered a high-value therapeutic target because its knockdown leads to significant inhibition of tumor growth and survival in preclinical models. Therapeutic strategies focusing on KLF5 mRNA include the use of small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) to trigger its degradation, as well as small molecules like ML264 that reduce its steady-state levels (PMID: 25605011). Beyond cancer, KLF5 mRNA is also implicated in vascular remodeling and cardiovascular diseases, making it a versatile but complex target due to its essential role in maintaining normal intestinal and skin epithelial integrity (PMID: 23505453).

Other names

BTEB2 mRNABasic transcription element-binding protein 2 mRNAIKLF mRNAIntestinal-enriched Krüppel-like factor mRNATranscription factor BTEB2 mRNA

RNA interference (siRNA-mediated degradation), antisense inhibition, or transcriptional suppression of mRNA synthesis leading to reduced protein levels.